Anika Therapeutics | ANIK - Equity Capital And Reserves


Anika Therapeutics reported $133.9M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agenus USD -271.11M 3.03M Dec/2025
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 568.42M 102.37M Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Integra LifeSciences USD 1.04B 1.06M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Smith & Nephew USD 5.54B 331M Dec/2025
Stryker USD 22.42B 635M Dec/2025
Surmodics USD 111.31M 7.59M Jun/2025
Veracyte USD 1.31B 51.91M Dec/2025
Xencor USD 635.59M 10.27M Dec/2025
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026